BNP Paribas Has $9.43 Million Stock Holdings in Boston Scientific Corporation $BSX

BNP Paribas decreased its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 16.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 94,114 shares of the medical equipment provider’s stock after selling 18,141 shares during the period. BNP Paribas’ holdings in Boston Scientific were worth $9,433,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. FWL Investment Management LLC acquired a new position in shares of Boston Scientific in the 2nd quarter worth approximately $26,000. Steph & Co. acquired a new stake in Boston Scientific in the 3rd quarter valued at $25,000. Murphy & Mullick Capital Management Corp grew its position in Boston Scientific by 200.0% in the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock valued at $25,000 after acquiring an additional 170 shares during the period. Financial Consulate Inc. bought a new stake in Boston Scientific in the third quarter valued at $25,000. Finally, United Community Bank raised its stake in Boston Scientific by 115.7% during the third quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 147 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors.

Boston Scientific News Roundup

Here are the key news stories impacting Boston Scientific this week:

• Neutral Sentiment: Zacks published a recap explaining why Boston Scientific dipped more than the broader market, noting recent volatility around the company. Useful for context on short‑term market reaction. Article Title
• Negative Sentiment: Citigroup lowered its price target for Boston Scientific to $94.00 — a formal analyst downgrade that can weigh on sentiment and may lead some funds to reprice positions. Article Title
• Negative Sentiment: Levi & Korsinsky (reported via PR Newswire) and others say a filed class action alleges Boston Scientific executives misrepresented U.S. electrophysiology procedure volumes — this is the substantive allegation that could lead to discovery, potential damages or settlement risk. Investors should watch pleadings and any company response. Article Title
• Negative Sentiment: Multiple plaintiff law firms (Rosen, Pomerantz, Glancy Prongay Wolke, Robbins Geller, Faruqi, Gross, Bernstein Liebhard, etc.) have issued shareholder alerts and deadline reminders (lead‑plaintiff motions due May 4, 2026). The coordinated outreach increases the likelihood of consolidated litigation and underscores ongoing legal scrutiny. Article Title

Insider Buying and Selling at Boston Scientific

In other news, CEO Michael F. Mahoney sold 160,901 shares of the company’s stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the transaction, the chief executive officer directly owned 1,411,735 shares in the company, valued at approximately $131,983,105.15. This represents a 10.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Stock Performance

Shares of NYSE:BSX opened at $69.15 on Friday. Boston Scientific Corporation has a twelve month low of $67.56 and a twelve month high of $109.50. The firm has a market cap of $102.61 billion, a PE ratio of 35.64, a price-to-earnings-growth ratio of 0.97 and a beta of 0.69. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.08 and a current ratio of 1.62. The business has a fifty day moving average of $82.47 and a 200-day moving average of $93.29.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.78 by $0.02. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The business had revenue of $5.29 billion for the quarter, compared to the consensus estimate of $5.29 billion. During the same quarter in the prior year, the company earned $0.70 EPS. The firm’s quarterly revenue was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. On average, equities research analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Wall Street Analyst Weigh In

BSX has been the topic of several analyst reports. UBS Group lowered their target price on shares of Boston Scientific from $140.00 to $120.00 and set a “buy” rating on the stock in a report on Thursday, February 5th. The Goldman Sachs Group set a $99.00 price target on shares of Boston Scientific in a report on Thursday, February 5th. Robert W. Baird decreased their price objective on shares of Boston Scientific from $118.00 to $101.00 and set an “outperform” rating on the stock in a research note on Thursday, February 5th. Stifel Nicolaus decreased their price objective on shares of Boston Scientific from $125.00 to $110.00 and set a “buy” rating on the stock in a research note on Wednesday, February 4th. Finally, Needham & Company LLC dropped their price objective on shares of Boston Scientific from $121.00 to $97.00 and set a “buy” rating for the company in a report on Thursday, February 5th. Two analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $108.00.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.